enarodustat enarodustat enarodustat (development code jtz-951; brand name enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (ckd). enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (hif-ph). enarodustatclinical datatrade namesenaroyother namesjtz-951legal statuslegal status rx-only (japan) identifiers iupac name 2-acetic acid cas number1262132-81-9pubchem cid50899324drugbank14985chemspider64835234uniijsk7tua223keggd11523chemblchembl4297619chemical and physical dataformulac17h16n4o4molar mass340.339 g·mol−13d model (jsmol)interactive image smiles c1=cc=c(c=c1)ccc2=cc(=o)c(=c3n2nc=n3)c(=o)ncc(=o)o inchi inchi=1s/c17h16n4o4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10h,6-7,9h2,(h,18,25)(h,19,20)(h,23,24)key:fjyrbjkwdxvhho-uhfffaoysa-n the drug was approved in september 2020 in japan for anemia associated with ckd and is currently in clinical development in the united states and south korea. the drug is being developed by japan tobacco and jw pharmaceutical.